Skip to main content
SpringerLink
Log in

Author’s Reply to Srinivas: “Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer”

  • Letter to the Editor
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Srinivas NR. Comment on: “Modeling the relationship between exposure to abiraterone and prostate-specific antigen dynamics in patients with metastatic castration-resistant prostate cancer”. Clin Pharmacokinet. 2016;. doi:10.1007/s40262-016-0468-2.

    PubMed  Google Scholar 

  2. Xu XS, Ryan CJ, Stuyckens K, et al. Modeling the relationship between exposure to abiraterone and prostate-specific antigen dynamics in patients with metastatic castration-resistant prostate cancer. Clin Pharmacokinet. 2016. [Epub ahead of print].

  3. Stuyckens K, Saad F, Xu XS, et al. Population pharmacokinetic analysis of abiraterone in chemotherapy-naive and docetaxel-treated patients with metastatic castration-resistant prostate cancer. Clin Pharmacokinet. 2014;53:1149–60.

    Article  CAS  PubMed  Google Scholar 

  4. Attard G, Reid AHM, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008;26:4563–71.

    Article  CAS  PubMed  Google Scholar 

  5. Ryan CJ, Smith MR, Fong L, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol. 2010;28:1481–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Reid AHM, Attard G, Danila DC, et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol. 2010;28:1489–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Danila DC, Morris MJ, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol. 2010;28:1496–501.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13:983–92.

    Article  CAS  PubMed  Google Scholar 

  9. Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152–60.

    Article  CAS  PubMed  Google Scholar 

  10. Carles J, Davis ID, de Bono JS, et al. Safety of long-term treatment of chemotherapy-naïve metastatic castration-resistant prostate cancer patients with abiraterone acetate plus prednisone for ≥4 years. Poster presented at the European Society of Medical Oncology 2016 Congress, 7–11 October 2016, Copenhagen, Denmark. Abstr No 740P

  11. Emamekhoo H, Li Z, Sharifi N. Clinical significance of D4A in prostate cancer therapy with abiraterone. Cell Cycle. 2015;14:3213–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Li Z, Bishop A, Alyamani M, et al. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. Nature. 2015;523:347–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Funding was provided by Janssen Research & Development. Writing assistance was provided by Shala Thomas, PhD, of PAREXEL and was funded by Janssen Global Services, LLC.

Author information

Authors and Affiliations

  1. Janssen Research & Development, 920 Route 202, Raritan, NJ, 08869, USA

    Steven Xu

  2. Janssen Research & Development, Beerse, Belgium

    Peter De Porre

Authors
  1. Steven Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter De Porre
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steven Xu.

Ethics declarations

Conflict of interest

XS Xu and P De Porre are employees of Janssen Research & Development and own stock in Johnson & Johnson.

Additional information

This is a reply to the letter available at doi:10.1007/s40262-016-0468-2.

This is a reply to the letter of the original article available at doi:10.1007/s40262-016-0425-0.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xu, S., De Porre, P. Author’s Reply to Srinivas: “Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer”. Clin Pharmacokinet 56, 213–214 (2017). https://doi.org/10.1007/s40262-016-0469-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40262-016-0469-1

Keywords

Search

Navigation